A Phase 1/2 interventional study of TB006 and Placebo in Alzheimer's Disease, sponsored by TrueBinding, Inc.. Completed at 18 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by TrueBinding, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 520th largest by enrollment of the 1,609 interventional ones that give a count, is one of 145 that started in 2021, is one of 67 in phase 1/2, and was the 1,371st registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,940 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 145 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,609 interventional studies, 160 across the 309 observational. Of the 1,378 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,940 have an industry lead sponsor. The 10 most frequent:
TrueBinding, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
TrueBinding, Inc. has 4 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
165 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 165 to your calendar (.ics) → With an account.
Among the 1,940 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Part 1 of this study will be conducted to determine the safety, tolerability, and pharmacokinetic (PK) profile of multiple doses of TB006, as well as the maximum tolerated dose of TB006, and to assess the immunogenicity of TB006 (production of anti-TB006 antibody). Part 2 of this study will be conducted to determine the clinical efficacy of TB006 in participants with mild to severe Alzheimer's Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of Alzheimer's Disease (AD) consistent with the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to 1 of 3 ascending dose groups to receive a total of 5 once-weekly doses of TB006, infused over 1 hour.
Drug: TB006
Participants will be randomized to receive 5 once-weekly doses of matching placebo.
Drug: Placebo
Participants will receive the highest safe and well-tolerated dose identified in Part 1, infused over 1 hour. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).
Drug: TB006
Participants will be randomized to receive matching placebo. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).
Drug: Placebo
intravenous infusion
intravenous infusion
Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.
Time frame: Up to Day 104
Part 1: Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatine Kinase (CK)
Blood samples were collected for analysis of following clinical chemistry parameters including ALT, ALP, AST and CK. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein
Blood samples were collected for analysis of following clinical chemistry parameters including albumin and protein. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL (High Density Lipoprotein) Cholesterol, LDL (Low Density Lipoprotein) Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen
Blood samples were collected for analysis of following clinical chemistry parameters including Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C
Blood samples were collected for analysis of following clinical chemistry parameters including Hemoglobin A1C. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Clinical Chemistry Parameters: Potassium and Sodium
Blood samples were collected for analysis of following clinical chemistry parameters including Potassium and Sodium. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin
Blood samples were collected for analysis of following clinical chemistry parameters including Thyrotropin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
Blood samples were collected for analysis of following hematology parameters including Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Hemoglobin (Ery. MCH)
Blood samples were collected for analysis of following hematology parameter: Ery. MCH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were collected for analysis of following hematology parameter: Hematocrit. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes and Reticulocytes
Blood samples were collected for analysis of following hematology parameter: Erythrocytes and Reticulocytes. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Volume (Ery. MCV)
Blood samples were collected for analysis of following hematology parameter: Ery. MCV. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Hematology Parameter: Hemoglobin
Blood samples were collected for analysis of following hematology parameter: Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Urine Potential of Hydrogen (pH)
Urine samples were collected for analysis of Urine pH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Urine Specific Gravity
Urine samples were collected for analysis of Urine specific gravity. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Urobilinogen
Urine samples were collected for analysis of Urobilinogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 1: Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Vital signs including DBP and SBP was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
Time frame: Baseline and Up to Day 104
Part 1: Change From Baseline in Respiratory Rate
Vital signs including respiratory rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
Time frame: Baseline and Up to Day 104
Part 1: Change From Baseline in Temperature
Vital signs including temperature was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
Time frame: Baseline and Up to Day 104
Part 1: Change From Baseline in Heart Rate
Vital signs including heart rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
Time frame: Baseline and Up to Day 104
Part 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate
12-lead ECG measurements was obtained using an ECG machine that automatically calculates the heart rate. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value value.
Time frame: Baseline and Up to Day 104
Part 1: Change From Baseline in ECG Parameters
12-lead ECG measurements was obtained using an ECG machine that automatically calculates the PR interval, QRS duration, QT interval and QT Corrected using Bazett's formula (QTcB). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
Time frame: Baseline and Up to Day 104
Part 1: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is an interview-based instrument to systematically assess suicidal ideation and suicidal behavior. Number of participants that have an affirmative response to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) were reported. The total score ranges from 0 (no ideation present) to 5 (active suicidal ideation with specific plan and intent); higher scores indicate worse symptoms.
Time frame: Up to Day 104
Part 1: Number of Participants With Clinically Significant Physical Examination Findings
A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.
Time frame: Up to Day 104
Part 1: Number of Participants With Clinically Significant Neurological Examination Findings
The neurological examination assessed mental status, motor and sensory skills, hearing and speech, vision, coordination, and balance. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.
Time frame: Up to Day 104
Part 1: Dose Normalized Area Under the Concentration Time Curve Over a Dosing Interval (AUCtau) of TB006
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis. AUCtau normalized to the actual administered dose is presented. The AUCtau was divided by the actual dose strength to get the normalized area under the concentration-time curve.
Time frame: Day 1 and Day 29
Part 1: Time at Which Maximum Plasma Concentration Occurs (Tmax) of TB006
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: At Days 1, 8 and 29
Part 1: Dose Normalized Maximum Observed Plasma Concentration (Cmax) of TB006
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis. Cmax normalized to the actual administered dose is presented. The Cmax was divided by the actual dose strength to get the normalized maximum observed plasma concentration.
Time frame: At Days 1, 8 and 29
Part 1: Concentration at the End of a Dosing Interval (Ctrough) of TB006
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Day 8 and Day 29
Part 1: Terminal Elimination Phase Half-life (t1/2) of TB006
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: At Day 29
Part 1: Total Clearance (CL) of TB006
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: At Day 29
Part 1: Volume of Distribution (Vd) of TB006
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: At Day 29
Part 1: Number of Participants With Anti-TB006 Antibodies (Immunogenicity of TB006)
Plasma samples were collected at indicated time points for the determination of anti-TB006 antibodies. Plasma samples were screened for antibodies binding to TB006 and the titer of confirmed positive samples has been reported.
Time frame: Day 1 (Predose), Day 8 (Predose), Day 36 and Day 104
Part 2: Change From Baseline Through Day 104 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score
The Clinical Dementia Rating was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain was rated on a five-point scale of functioning as follows: 0: no impairment; 0.5: questionable impairment; 1: mild impairment; 2: moderate impairment; and 3: severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes was based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. Baseline was defined as the last available value prior to the subject receiving the first study drug infusion on Day 1. Change from Baseline value was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline through Day 104
Part 2: Change From Baseline Through Day 36 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score
The Clinical Dementia Rating was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain was rated on a five-point scale of functioning as follows: 0: no impairment; 0.5: questionable impairment; 1: mild impairment; 2: moderate impairment; and 3: severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes was based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. Baseline was defined as the last available value prior to the subject receiving the first study drug infusion on Day 1. Change from Baseline value was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline through Day 36
Part 2: Percentage of Responders on the Clinical Dementia Rating Scale - Sum of Boxes
The Clinical Dementia Rating is obtained through semi-structured interviews of participants and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes is based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. A responder was defined as a participant with at least 1 point improvement from Baseline on the Sum of Boxes score. Percentage of responders on the Clinical Dementia Rating Scale - Sum of Boxes has been presented.
Time frame: At Days 36 and 104
Part 2: Change From Baseline on Mini-Mental State Examination (MMSE) Score
The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia participants. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from Baseline. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and at Days 36 and 104
Part 2: Change From Baseline on the Neuropsychiatric Inventory (NPI) Score
The NPI was a questionnaire that quantified psychiatric symptoms and behavioral disorders in dementia. A total of 12 items (the original NPI-10 consisting of 10 behavioral domains: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor behavior, The NPI total score was calculated by adding the scores of the domains (each domain scores ranges from 0 to 12). The NPI total score ranges from 0 to 120 with higher scores indicating greater behavioral impairment. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and at Days 36 and 104
Part 2: Number of Participants With AEs and SAEs
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.
Time frame: Up to Day 104
Part 2: Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK
Blood samples were collected for analysis of following clinical chemistry parameters including ALT, ALP, AST and CK. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein
Blood samples were collected for analysis of following clinical chemistry parameters including albumin and protein. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen
Blood samples were collected for analysis of following clinical chemistry parameters including Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C
Blood samples were collected for analysis of following clinical chemistry parameter including Hemoglobin A1C. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Clinical Chemistry Parameters: Potassium and Sodium
Blood samples were collected for analysis of following clinical chemistry parameters including Potassium and Sodium. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin
Blood samples were collected for analysis of following clinical chemistry parameter including Thyrotropin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
Blood samples were collected for analysis of following hematology parameters including Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Hematology Parameter: Ery. MCH
Blood samples were collected for analysis of following hematology parameter: Ery. MCH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Hematology Parameter: Ery. MCV
Blood samples were collected for analysis of following hematology parameter: Ery. MCV. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes and Reticulocytes
Blood samples were collected for analysis of following hematology parameter: Erythrocytes and Reticulocytes. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were collected for analysis of following hematology parameter: Hematocrit. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Hematology Parameter: Hemoglobin
Blood samples were collected for analysis of following hematology parameter: Hemoglobin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Urine pH
Urine samples were collected for analysis of Urine pH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Urine Specific Gravity
Urine samples were collected for analysis of Urine specific gravity. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in Urobilinogen
Urine samples were collected for analysis of Urobilinogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
Time frame: Baseline and up to Day 104
Part 2: Change From Baseline in DBP and SBP
Vital signs including DBP and SBP was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
Time frame: Baseline and Up to Day 104
Part 2: Change From Baseline in Respiratory Rate
Vital signs including respiratory rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
Time frame: Baseline and Up to Day 104
Part 2: Change From Baseline in Temperature
Vital signs including temperature was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
Time frame: Baseline and Up to Day 104
Part 2: Change From Baseline in Heart Rate
Vital signs including heart rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
Time frame: Baseline and Up to Day 104
Part 2: Change From Baseline in ECG Parameters
12-lead ECG measurements was obtained using an ECG machine that automatically calculates the PR interval, QRS duration, QT interval and QTcB. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
Time frame: Baseline and Up to Day 104
Part 2: Change From Baseline in ECG Mean Heart Rate
12-lead ECG measurements was obtained using an ECG machine that automatically calculates the heart rate. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
Time frame: Baseline and Up to Day 104
Part 2: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS
The C-SSRS is an interview-based instrument to systematically assess suicidal ideation and suicidal behavior. Number of participants that have an affirmative response to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) were reported. The total score ranges from 0 (no ideation present) to 5 (active suicidal ideation with specific plan and intent); higher scores indicate worse symptoms.
Time frame: Up to Day 104
Part 2: Number of Participants With Clinically Significant Physical Examination Findings
A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.
Time frame: Up to Day 104
Part 2: Number of Participants With Clinically Significant Neurological Examination Findings
The neurological examination assessed mental status, motor and sensory skills, hearing and speech, vision, coordination, and balance. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.
Time frame: Up to Day 104
Part 2: Ctrough of TB006
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Day 29
Part 2: t1/2 of TB006
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Day 29
Part 2: Cmax of TB006
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Day 1 and Day 29
This was a multi-center study conducted at various centers across United States (US).
| Milestone | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Started | 7 | 6 | 6 | 6 | 0 | 0 |
| Completed | 6 | 6 | 6 | 5 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 63 | 66 |
| Completed | 0 | 0 | 0 | 0 | 58 | 64 |
| Not completed | 0 | 0 | 0 | 0 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 | 0 |
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.
| Participants | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Any AE | 5 | 4 | 1 | 2 |
| Any SAE | 1 | 0 | 0 | 0 |
Blood samples were collected for analysis of following clinical chemistry parameters including ALT, ALP, AST and CK. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| International Units per Liter | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| ALT | -1.7 ± 2.21 | -5.5 ± 5.32 | -0.7 ± 10.33 | 5.4 ± 14.79 |
| ALP | -0.6 ± 9.11 | -4.0 ± 5.59 | -2.2 ± 10.05 | 9.0 ± 15.98 |
| AST | -0.1 ± 2.27 | -3.8 ± 5.23 | -1.3 ± 7.61 | 3.2 ± 13.65 |
| CK | 22.0 ± 39.27 | 0.5 ± 44.37 | 0.3 ± 65.56 | -10.4 ± 14.03 |
Blood samples were collected for analysis of following clinical chemistry parameters including albumin and protein. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| grams per deciliter | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Albumin | -0.14 ± 0.199 | 0.02 ± 0.098 | -0.03 ± 0.367 | -0.04 ± 0.167 |
| Protein | -0.20 ± 0.316 | 0.12 ± 0.183 | -0.05 ± 0.589 | -0.08 ± 0.363 |
Blood samples were collected for analysis of following clinical chemistry parameters including Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| milligrams per deciliter | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Calcium | -0.13 ± 0.373 | 0.17 ± 0.280 | -0.02 ± 0.360 | -0.18 ± 0.356 |
| Cholesterol | -15.4 ± 21.62 | -2.7 ± 10.35 | 6.2 ± 74.37 | -13.4 ± 47.79 |
| Creatinine | 0.047 ± 0.081 | 0.153 ± 0.377 | 0.108 ± 0.143 | -0.040 ± 0.142 |
| Direct Bilirubin | -0.007 ± 0.032 | -0.003 ± 0.033 | 0.000 ± 0.020 | -0.022 ± 0.030 |
| Glucose | 34.3 ± 55.23 | -15.0 ± 18.51 | 21.3 ± 45.45 | 8.2 ± 49.94 |
| HDL Cholesterol | -3.6 ± 5.19 | -3.0 ± 4.65 | 0.2 ± 13.98 | 4.0 ± 17.13 |
| LDL Cholesterol | -9.0 ± 9.04 | -1.8 ± 9.33 | -3.5 ± 64.62 | -14.8 ± 46.23 |
| Total Bilirubin | -0.036 ± 0.093 | -0.005 ± 0.227 | 0.032 ± 0.132 | -0.134 ± 0.225 |
| Triglycerides | -23.3 ± 69.65 | 12.2 ± 17.72 | 18.7 ± 104.95 | -23.8 ± 39.06 |
| Urea Nitrogen | -0.40 ± 2.171 | 6.95 ± 8.277 | 2.43 ± 3.449 | 1.30 ± 4.266 |
Blood samples were collected for analysis of following clinical chemistry parameters including Hemoglobin A1C. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| percentage of glycosylated hemoglobin | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C | 0.06 ± 0.162 | -0.02 ± 0.567 | -0.33 ± 0.625 | -0.14 ± 1.011 |
Blood samples were collected for analysis of following clinical chemistry parameters including Potassium and Sodium. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| Millimoles per liter | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Potassium | 0.10 ± 0.476 | -0.15 ± 0.288 | 0.07 ± 0.378 | 0.02 ± 0.259 |
| Sodium | -1.0 ± 2.24 | 0.8 ± 1.72 | -1.2 ± 2.56 | -1.2 ± 2.39 |
Blood samples were collected for analysis of following clinical chemistry parameters including Thyrotropin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| micro-international units per milliliter | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin | 1.209 ± 3.114 | -0.343 ± 0.298 | -0.370 ± 1.312 | -0.246 ± 0.372 |
Blood samples were collected for analysis of following hematology parameters including Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| 10^3 cells per microliter | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Basophils | -0.023 ± 0.015 | -0.005 ± 0.019 | 0.005 ± 0.028 | 0.006 ± 0.013 |
| Eosinophils | 0.014 ± 0.138 | 0.003 ± 0.068 | 0.038 ± 0.089 | 0.030 ± 0.173 |
| Leukocytes | -0.76 ± 0.650 | 0.00 ± 1.292 | 0.40 ± 1.563 | -0.28 ± 1.092 |
| Lymphocytes | -0.264 ± 0.188 | -0.025 ± 0.241 | -0.037 ± 1.265 | -0.036 ± 0.250 |
| Monocytes | -0.094 ± 0.118 | -0.017 ± 0.114 | 0.032 ± 0.108 | 0.028 ± 0.062 |
| Neutrophils | -0.396 ± 0.719 | 0.078 ± 1.171 | 0.368 ± 0.641 | -0.318 ± 1.145 |
| Platelets | -9.1 ± 37.53 | 5.0 ± 37.25 | -9.6 ± 89.83 | -4.5 ± 50.16 |
Blood samples were collected for analysis of following hematology parameter: Ery. MCH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| picograms | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Hemoglobin (Ery. MCH) | -0.40 ± 1.134 | -0.05 ± 0.579 | 1.02 ± 3.511 | -0.34 ± 0.631 |
Blood samples were collected for analysis of following hematology parameter: Hematocrit. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| Percentage | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Hematology Parameter: Hematocrit | 0.69 ± 2.563 | 1.18 ± 2.105 | 1.18 ± 7.919 | 0.32 ± 2.493 |
Blood samples were collected for analysis of following hematology parameter: Erythrocytes and Reticulocytes. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| 10^6 cells per microliter | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Erythrocytes | 0.039 ± 0.401 | 0.012 ± 0.219 | -0.108 ± 0.625 | 0.024 ± 0.211 |
| Reticulocytes | -0.011 ± 0.017 | -0.005 ± 0.004 | -0.008 ± 0.008 | -0.005 ± 0.009 |
Blood samples were collected for analysis of following hematology parameter: Ery. MCV. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| femtoliters | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Volume (Ery. MCV) | 0.80 ± 1.926 | 2.45 ± 1.343 | 5.42 ± 5.724 | 0.20 ± 2.699 |
Blood samples were collected for analysis of following hematology parameter: Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| grams per deciliter | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Hematology Parameter: Hemoglobin | -0.06 ± 0.779 | 0.00 ± 0.465 | 0.08 ± 3.260 | -0.10 ± 0.877 |
Urine samples were collected for analysis of Urine pH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| potential of Hydrogen | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Urine Potential of Hydrogen (pH) | -0.36 ± 1.215 | 0.40 ± 1.294 | -0.50 ± 1.612 | -0.80 ± 0.975 |
Urine samples were collected for analysis of Urine specific gravity. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| Ratio | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Urine Specific Gravity | 0.003 ± 0.008 | 0.003 ± 0.006 | 0.004 ± 0.011 | 0.007 ± 0.010 |
Urine samples were collected for analysis of Urobilinogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| milligrams per deciliter | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Urobilinogen | 0.00 ± 0.462 | -0.16 ± 0.358 | -0.13 ± 0.602 | 0.00 ± 0.000 |
Vital signs including DBP and SBP was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
| Millimeters of mercury | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| DBP | -2.1 ± 12.06 | -2.3 ± 10.37 | -1.0 ± 3.03 | -7.2 ± 9.09 |
| SBP | -10.4 ± 13.39 | 3.5 ± 9.61 | -6.2 ± 13.17 | 2.2 ± 17.74 |
Vital signs including respiratory rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
| breaths per minute | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Respiratory Rate | 0.0 ± 0.00 | -0.7 ± 2.16 | 0.3 ± 1.03 | -0.2 ± 1.30 |
Vital signs including temperature was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
| degrees Celsius | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Temperature | 0.26 ± 0.351 | -0.37 ± 0.350 | -0.03 ± 0.833 | -0.22 ± 0.130 |
Vital signs including heart rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
| Beats per minute | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Heart Rate | -2.0 ± 8.00 | 3.3 ± 3.72 | 4.0 ± 5.73 | -4.2 ± 9.50 |
12-lead ECG measurements was obtained using an ECG machine that automatically calculates the heart rate. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value value.
| Beats per minute | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate | -4.8 ± 5.78 | -0.9 ± 4.00 | 3.0 ± 3.82 | -3.4 ± 4.87 |
12-lead ECG measurements was obtained using an ECG machine that automatically calculates the PR interval, QRS duration, QT interval and QT Corrected using Bazett's formula (QTcB). Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
| milliseconds | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| PR Interval | 4.8 ± 10.07 | 0.7 ± 5.90 | -11.0 ± 14.74 | 14.9 ± 5.16 |
| QRS Duration | 0.3 ± 3.07 | 1.1 ± 5.27 | 1.0 ± 7.16 | -4.1 ± 13.50 |
| QT Interval | 21.9 ± 12.72 | -2.9 ± 10.48 | 0.3 ± 9.36 | -5.0 ± 11.47 |
| QTcB Interval | 8.1 ± 11.37 | -6.6 ± 12.98 | 9.9 ± 11.50 | -15.2 ± 4.15 |
The C-SSRS is an interview-based instrument to systematically assess suicidal ideation and suicidal behavior. Number of participants that have an affirmative response to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) were reported. The total score ranges from 0 (no ideation present) to 5 (active suicidal ideation with specific plan and intent); higher scores indicate worse symptoms.
| Participants | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Wish to be dead | 0 | 0 | 0 | 0 |
| Non-specific active suicidal thoughts | 0 | 0 | 0 | 0 |
| Active suicidal ideation without any methods without intent to act | 0 | 0 | 0 | 0 |
| Active suicidal ideation with some intent to act, without specific plan | 0 | 0 | 0 | 0 |
| Active suicidal ideation with specific plan and intent | 0 | 0 | 0 | 0 |
| Any suicidal behavior | 0 | 0 | 0 | 0 |
| Actual attempt | 0 | 0 | 0 | 0 |
| Interrupted attempt | 0 | 0 | 0 | 0 |
| Aborted attempt | 0 | 0 | 0 | 0 |
| Preparatory acts or behavior | 0 | 0 | 0 | 0 |
| Most recent attempt | 0 | 0 | 0 | 0 |
| First attempt | 0 | 0 | 0 | 0 |
| Lethal attempt | 0 | 0 | 0 | 0 |
A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.
No measurements were reported for this outcome.
The neurological examination assessed mental status, motor and sensory skills, hearing and speech, vision, coordination, and balance. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.
No measurements were reported for this outcome.
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis. AUCtau normalized to the actual administered dose is presented. The AUCtau was divided by the actual dose strength to get the normalized area under the concentration-time curve.
| hours*micrograms/milliliter/milligram | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw |
|---|---|---|---|
| Day 1 | 39.81 ± 23.17 | 29.87 ± 38.15 | 11.93 ± 100.21 |
| Day 29 | 125.92 ± 18.01 | 117.75 ± 24.52 | 82.95 ± 18.18 |
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
| hours | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw |
|---|---|---|---|
| Day 1 | 1.12 (1.0 to 7.0) | 2.01 (1.1 to 5.0) | 2.00 (1.0 to 5.0) |
| Day 8 | 1.23 (1.0 to 2.0) | 1.60 (1.2 to 5.0) | 2.50 (1.1 to 5.0) |
| Day 29 | 2.03 (1.1 to 5.1) | 2.18 (1.1 to 7.0) | 2.00 (1.0 to 7.0) |
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis. Cmax normalized to the actual administered dose is presented. The Cmax was divided by the actual dose strength to get the normalized maximum observed plasma concentration.
| micrograms/milliliter/milligram | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw |
|---|---|---|---|
| Day 1 | 0.36 ± 25.72 | 0.29 ± 36.97 | 0.07 ± 105.32 |
| Day 8 | 0.58 ± 27.57 | 0.49 ± 26.77 | 0.30 ± 30.27 |
| Day 29 | 0.95 ± 18.15 | 0.85 ± 22.89 | 0.61 ± 13.40 |
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
| micrograms per milliliter | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw |
|---|---|---|---|
| Day 8 | 25.77 ± 21.23 | 71.44 ± 20.75 | 68.62 ± 70.91 |
| Day 29 | 76.69 ± 19.62 | 204.77 ± 20.46 | 348.20 ± 22.34 |
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
| hours | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw |
|---|---|---|---|
| Part 1: Terminal Elimination Phase Half-life (t1/2) of TB006 | 711.49 ± 19.87 | 757.59 ± 22.80 | 739.50 ± 14.90 |
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
| milliliters per hour | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw |
|---|---|---|---|
| Part 1: Total Clearance (CL) of TB006 | 7.94 ± 17.06 | 8.49 ± 19.27 | 12.06 ± 19.68 |
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
| milliliters | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw |
|---|---|---|---|
| Part 1: Volume of Distribution (Vd) of TB006 | 8151.47 ± 21.38 | 9282.51 ± 28.97 | 13617.70 ± 30.63 |
Plasma samples were collected at indicated time points for the determination of anti-TB006 antibodies. Plasma samples were screened for antibodies binding to TB006 and the titer of confirmed positive samples has been reported.
| Participants | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo |
|---|---|---|---|---|
| Day 1 (Predose) | 0 | 0 | 0 | 0 |
| Day 8 (Predose) | 0 | 0 | 0 | 0 |
| Day 36 | 0 | 0 | 0 | 0 |
| Day 104 | 1 | 0 | 0 | 0 |
The Clinical Dementia Rating was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain was rated on a five-point scale of functioning as follows: 0: no impairment; 0.5: questionable impairment; 1: mild impairment; 2: moderate impairment; and 3: severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes was based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. Baseline was defined as the last available value prior to the subject receiving the first study drug infusion on Day 1. Change from Baseline value was obtained by subtracting Baseline value from post-dose visit value.
| Scores on a scale | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline Through Day 104 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score | 0.01 ± 0.147 | 0.35 ± 0.142 |
The Clinical Dementia Rating was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain was rated on a five-point scale of functioning as follows: 0: no impairment; 0.5: questionable impairment; 1: mild impairment; 2: moderate impairment; and 3: severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes was based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. Baseline was defined as the last available value prior to the subject receiving the first study drug infusion on Day 1. Change from Baseline value was obtained by subtracting Baseline value from post-dose visit value.
| Scores on a scale | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline Through Day 36 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score | -0.16 ± 0.162 | 0.23 ± 0.157 |
The Clinical Dementia Rating is obtained through semi-structured interviews of participants and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. The Clinical Dementia Rating Scale - Sum of Boxes is based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes, and higher total scores represent worse outcomes. A responder was defined as a participant with at least 1 point improvement from Baseline on the Sum of Boxes score. Percentage of responders on the Clinical Dementia Rating Scale - Sum of Boxes has been presented.
| Percentage of responders | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Day 36 | 25.4 | 9.7 |
| Day 104 | 22.4 | 15.3 |
The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia participants. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from Baseline. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| Scores on a scale | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Day 36 | 1.2 ± 2.59 | 0.2 ± 2.52 |
| Day 104 | 1.0 ± 3.10 | 0.6 ± 2.97 |
The NPI was a questionnaire that quantified psychiatric symptoms and behavioral disorders in dementia. A total of 12 items (the original NPI-10 consisting of 10 behavioral domains: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor behavior, The NPI total score was calculated by adding the scores of the domains (each domain scores ranges from 0 to 12). The NPI total score ranges from 0 to 120 with higher scores indicating greater behavioral impairment. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| Scores on a scale | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Day 36 | -2.5 ± 8.10 | -0.8 ± 9.12 |
| Day 104 | -3.5 ± 11.47 | -1.1 ± 6.79 |
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.
| Participants | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Any AE | 28 | 17 |
| Any SAE | 4 | 1 |
Blood samples were collected for analysis of following clinical chemistry parameters including ALT, ALP, AST and CK. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| International Units per Liter | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| ALT | -0.5 ± 12.88 | -0.4 ± 5.40 |
| ALP | 1.0 ± 12.01 | 0.0 ± 11.92 |
| AST | -0.4 ± 10.44 | -0.5 ± 3.58 |
| CK | -14.3 ± 77.24 | 6.3 ± 52.07 |
Blood samples were collected for analysis of following clinical chemistry parameters including albumin and protein. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| grams per deciliter | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Albumin | -0.10 ± 0.300 | -0.01 ± 0.251 |
| Protein | -0.10 ± 0.470 | 0.00 ± 0.404 |
Blood samples were collected for analysis of following clinical chemistry parameters including Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| milligrams per deciliter | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Calcium | -0.09 ± 0.437 | -0.11 ± 0.432 |
| Cholesterol | -5.8 ± 32.30 | 0.3 ± 28.17 |
| Creatinine | 0.014 ± 0.098 | -0.017 ± 0.124 |
| Direct Bilirubin | 0.005 ± 0.037 | -0.006 ± 0.030 |
| Glucose | -5.6 ± 26.98 | -6.3 ± 27.92 |
| HDL Cholesterol | -2.4 ± 8.49 | -0.3 ± 8.26 |
| LDL Cholesterol | -7.5 ± 24.64 | -4.6 ± 23.63 |
| Total Bilirubin | 0.023 ± 0.157 | -0.014 ± 0.128 |
| Triglycerides | -9.2 ± 73.95 | -0.4 ± 46.29 |
| Urea Nitrogen | 0.41 ± 3.817 | -1.03 ± 4.777 |
Blood samples were collected for analysis of following clinical chemistry parameter including Hemoglobin A1C. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| percentage of glycosylated hemoglobin | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C | -0.06 ± 0.638 | 0.07 ± 0.555 |
Blood samples were collected for analysis of following clinical chemistry parameters including Potassium and Sodium. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| Millimoles per liter | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Potassium | -0.14 ± 0.469 | -0.13 ± 0.521 |
| Sodium | -0.7 ± 2.11 | -0.7 ± 3.05 |
Blood samples were collected for analysis of following clinical chemistry parameter including Thyrotropin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| micro-international units per milliliter | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin | -0.118 ± 0.619 | 0.134 ± 1.000 |
Blood samples were collected for analysis of following hematology parameters including Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| 10^3 cells per microliter | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Basophils | -0.004 ± 0.027 | -0.002 ± 0.022 |
| Eosinophils | -0.008 ± 0.113 | -0.040 ± 0.130 |
| Leukocytes | -0.26 ± 1.383 | -0.02 ± 1.244 |
| Lymphocytes | -0.118 ± 0.392 | -0.053 ± 0.411 |
| Monocytes | -0.021 ± 0.109 | 0.003 ± 0.107 |
| Neutrophils | -0.109 ± 1.295 | 0.067 ± 1.206 |
| Platelets | -1.9 ± 32.08 | -12.1 ± 46.27 |
Blood samples were collected for analysis of following hematology parameter: Ery. MCH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| picograms | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Hematology Parameter: Ery. MCH | 0.19 ± 0.775 | 0.51 ± 1.045 |
Blood samples were collected for analysis of following hematology parameter: Ery. MCV. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| femtoliters | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Hematology Parameter: Ery. MCV | 1.54 ± 2.743 | 2.04 ± 3.412 |
Blood samples were collected for analysis of following hematology parameter: Erythrocytes and Reticulocytes. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| 10^6 cells per microliter | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Erythrocytes | -0.028 ± 0.269 | 0.024 ± 0.228 |
| Reticulocytes | 0.001 ± 0.012 | -0.003 ± 0.012 |
Blood samples were collected for analysis of following hematology parameter: Hematocrit. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| Percentage | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Hematology Parameter: Hematocrit | 0.41 ± 2.735 | 1.11 ± 2.403 |
Blood samples were collected for analysis of following hematology parameter: Hemoglobin. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| grams per deciliter | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Hematology Parameter: Hemoglobin | 0.00 ± 0.766 | 0.29 ± 0.827 |
Urine samples were collected for analysis of Urine pH. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| potential of Hydrogen | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Urine pH | -0.13 ± 0.788 | 0.18 ± 0.791 |
Urine samples were collected for analysis of Urine specific gravity. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| Ratio | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Urine Specific Gravity | 0.002 ± 0.010 | 0.001 ± 0.008 |
Urine samples were collected for analysis of Urobilinogen. Baseline was defined as Day 1. Change from Baseline was obtained by subtracting Baseline value from post-dose visit value.
| milligrams per deciliter | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Urobilinogen | 0.07 ± 0.313 | 0.05 ± 0.354 |
Vital signs including DBP and SBP was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
| Millimeters of mercury | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| DBP | 0.8 ± 6.42 | 0.7 ± 9.48 |
| SBP | 1.4 ± 15.02 | 0.0 ± 15.57 |
Vital signs including respiratory rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
| breaths per minute | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Respiratory Rate | 0.1 ± 0.97 | 0.2 ± 0.97 |
Vital signs including temperature was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
| degrees Celsius | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Temperature | 0.01 ± 0.489 | -0.03 ± 0.461 |
Vital signs including heart rate was measured by at least 5 minutes of rest with the participant in a quiet setting without distractions (eg, television, cell phones). Blood pressure measurements were taken with the participant in the sitting position. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
| Beats per minute | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Heart Rate | -4.2 ± 8.59 | -2.1 ± 7.86 |
12-lead ECG measurements was obtained using an ECG machine that automatically calculates the PR interval, QRS duration, QT interval and QTcB. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
| milliseconds | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| PR Interval | -1.6 ± 13.17 | 2.1 ± 18.32 |
| QRS Duration | -2.2 ± 13.31 | -1.4 ± 7.71 |
| QT Interval | 4.2 ± 26.29 | 3.9 ± 20.28 |
| QTcB Interval | -2.0 ± 18.01 | -1.7 ± 15.99 |
12-lead ECG measurements was obtained using an ECG machine that automatically calculates the heart rate. Baseline was defined as the last available value prior to the participant receiving the first study drug infusion on Day 1. Change from Baseline was obtained by subtracting the Baseline value from post-dose visit value.
| Beats per minute | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in ECG Mean Heart Rate | -1.8 ± 8.87 | -1.3 ± 7.40 |
The C-SSRS is an interview-based instrument to systematically assess suicidal ideation and suicidal behavior. Number of participants that have an affirmative response to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) were reported. The total score ranges from 0 (no ideation present) to 5 (active suicidal ideation with specific plan and intent); higher scores indicate worse symptoms.
| Participants | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|
| Wish to be dead | 0 | 0 |
| Non-specific active suicidal thoughts | 0 | 0 |
| Active suicidal ideation without any methods without intent to act | 0 | 0 |
| Active suicidal ideation with some intent to act, without specific plan | 0 | 0 |
| Active suicidal ideation with specific plan and intent | 0 | 0 |
| Any suicidal behavior | 0 | 0 |
| Actual attempt | 0 | 0 |
| Interrupted attempt | 0 | 0 |
| Aborted attempt | 0 | 0 |
| Preparatory acts or behavior | 0 | 0 |
| Most recent attempt | 0 | 0 |
| First attempt | 0 | 0 |
| Lethal attempt | 0 | 0 |
A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.
No measurements were reported for this outcome.
The neurological examination assessed mental status, motor and sensory skills, hearing and speech, vision, coordination, and balance. This analysis was planned but data was not captured in the database. Abnormal changes were captured as adverse events if they were clinically significant.
No measurements were reported for this outcome.
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
| micrograms per milliliter | Part 2: TB006 1000 mg qw |
|---|---|
| Part 2: Ctrough of TB006 | 395.82 ± 35.88 |
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
| hours | Part 2: TB006 1000 mg qw |
|---|---|
| Part 2: t1/2 of TB006 | 756.78 ± 22.05 |
Blood samples were collected at indicated time points for PK analysis of TB006. PK parameters were analyzed using standard non-compartmental analysis.
| Micrograms per milliliter | Part 2: TB006 1000 mg qw |
|---|---|
| Day 1 | 339.17 ± 23.82 |
| Day 29 | 731.55 ± 25.13 |
Collected over Up to Day 104. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: TB006 140 Milligrams (mg) Weekly (qw) | 0/7 (0%) | 1/7 (14.3%) | 5/7 (71.4%) |
| Part 1: TB006 420 mg qw | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 1: TB006 1000 mg qw | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1: Placebo | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 2: TB006 1000 mg qw | 1/63 (1.6%) | 4/63 (6.3%) | 28/63 (44.4%) |
| Part 2: Placebo | 0/66 (0%) | 1/66 (1.5%) | 17/66 (25.8%) |
| Event | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 1/7 | 0/6 | 0/6 | 0/6 | 0/63 | 0/66 |
| Atrial fibrillationCardiac disorders | 0/7 | 0/6 | 0/6 | 0/6 | 1/63 | 0/66 |
| CholelithiasisHepatobiliary disorders | 0/7 | 0/6 | 0/6 | 0/6 | 1/63 | 0/66 |
| Clostridium difficile colitisInfections and infestations | 0/7 | 0/6 | 0/6 | 0/6 | 1/63 | 0/66 |
| PneumoniaInfections and infestations | 0/7 | 0/6 | 0/6 | 0/6 | 1/63 | 0/66 |
| SepsisInfections and infestations | 0/7 | 0/6 | 0/6 | 0/6 | 1/63 | 0/66 |
| HyponatraemiaMetabolism and nutrition disorders | 0/7 | 0/6 | 0/6 | 0/6 | 1/63 | 0/66 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/7 | 0/6 | 0/6 | 0/6 | 1/63 | 0/66 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/7 | 0/6 | 0/6 | 0/6 | 1/63 | 0/66 |
| Metabolic encephalopathyNervous system disorders | 0/7 | 0/6 | 0/6 | 0/6 | 1/63 | 0/66 |
| Event | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo | Part 2: TB006 1000 mg qw | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/7 | 2/6 | 0/6 | 0/6 | 3/63 | 1/66 |
| Atrial fibrillationCardiac disorders | 0/7 | 0/6 | 1/6 | 0/6 | 1/63 | 0/66 |
| Abdominal pain upperGastrointestinal disorders | 0/7 | 1/6 | 0/6 | 0/6 | 0/63 | 0/66 |
| ProctitisGastrointestinal disorders | 0/7 | 1/6 | 0/6 | 0/6 | 0/63 | 0/66 |
| Blood urea increasedInvestigations | 1/7 | 1/6 | 0/6 | 0/6 | 0/63 | 0/66 |
| Blood creatinine increasedInvestigations | 0/7 | 1/6 | 0/6 | 0/6 | 2/63 | 1/66 |
| Blood glucose increasedInvestigations | 0/7 | 0/6 | 0/6 | 1/6 | 0/63 | 0/66 |
| Glycosylated haemoglobin increasedInvestigations | 0/7 | 0/6 | 0/6 | 1/6 | 0/63 | 0/66 |
| Urine analysis abnormalInvestigations | 0/7 | 0/6 | 0/6 | 1/6 | 0/63 | 1/66 |
| DizzinessNervous system disorders | 0/7 | 1/6 | 0/6 | 0/6 | 1/63 | 0/66 |
Safety Analysis Set comprised of all participants randomly assigned to study drug and who took at least 1 dose of study drug.
| Age, Continuous(Years) | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo | Part 2: TB006 1000 mg qw | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 72.3 ± 3.25 | 73.0 ± 10.41 | 71.5 ± 6.77 | 72.2 ± 6.74 | 73.5 ± 9.30 | 71.5 ± 7.65 | 72.2 ± 7.35 |
| Sex: Female, Male(Participants) | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo | Part 2: TB006 1000 mg qw | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 6 | 4 | 2 | 5 | 33 | 36 | 86 |
| Male | 1 | 2 | 4 | 1 | 30 | 30 | 68 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo | Part 2: TB006 1000 mg qw | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 5 | 3 | 27 | 39 | 75 |
| Not Hispanic or Latino | 7 | 5 | 1 | 3 | 35 | 26 | 77 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Part 1: TB006 140 Milligrams (mg) Weekly (qw) | Part 1: TB006 420 mg qw | Part 1: TB006 1000 mg qw | Part 1: Placebo | Part 2: TB006 1000 mg qw | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 1 | 4 | 6 | 13 |
| White | 5 | 5 | 6 | 5 | 57 | 60 | 138 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Oct 2022, 12 months.
Results were first posted in Nov 2023, 1 year 1 month after primary completion.
Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TB006
TrueBinding, Inc.